KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inovio Pharmaceuticals (INO) Net Cash Flow (2016 - 2025)

Inovio Pharmaceuticals (INO) has disclosed Net Cash Flow for 16 consecutive years, with $7.7 million as the latest value for Q4 2025.

  • Quarterly Net Cash Flow fell 82.54% to $7.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$21.5 million through Dec 2025, down 141.85% year-over-year, with the annual reading at -$21.5 million for FY2025, 141.85% down from the prior year.
  • Net Cash Flow hit $7.7 million in Q4 2025 for Inovio Pharmaceuticals, down from $12.2 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $44.1 million in Q4 2024 to a low of -$167.1 million in Q1 2021.
  • Historically, Net Cash Flow has averaged -$10.3 million across 5 years, with a median of -$8.3 million in 2022.
  • Biggest five-year swings in Net Cash Flow: skyrocketed 1081.83% in 2024 and later plummeted 592.49% in 2025.
  • Year by year, Net Cash Flow stood at $3.2 million in 2021, then surged by 657.96% to $24.3 million in 2022, then crashed by 118.47% to -$4.5 million in 2023, then surged by 1081.83% to $44.1 million in 2024, then plummeted by 82.54% to $7.7 million in 2025.
  • Business Quant data shows Net Cash Flow for INO at $7.7 million in Q4 2025, $12.2 million in Q3 2025, and -$15.6 million in Q2 2025.